CFLAR and cancer: We and others have reported that histone deacetylase inhibitors such as vorinostat trigger the rapid ubiquitination and degradation of FLIP, thus sensitising cells to TRAIL or chemotherapy.122, 170 Additionally, a number of chemotherapeutics and other anti-cancer agents downregulate FLIP expression via multiple mechanisms (reviewed by Safa183).